JPRN-UMIN000039992已完成未知
ong-term follow-up of the multicenter investigator-initiated clinical trial using cultivated autologous oral mucosal epithelial cell sheet (COMET01) transplantation for patients with limbal stem-cell deficiency - Long-term follow-up of the multicenter investigator-initiated clinical trial using cultivated autologous oral mucosal epithelial cell sheet (COMET01) transplantation for patients with limbal stem-cell deficiency
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients planning to participate in other clinical trials during the study participation 2) Patients who desire pregnancy during clinical studies 3) Patients determined to be inappropriate by physicians
研究者
相似试验
进行中（未招募）
不适用
ong-term follow-up (up to 3 years) to investigate the maintenance of efficacy and safety of AllerT, a drug based on modified peptides of Bet V 1, applied in two different dosages to subjects suffering from birch pollen allergy during the trial AN004Tong-term follow-up of desensitization by Specific ImmunoTherapy (SIT) received during the trial AN004T in subjects allergic to birch pollenMedDRA version: 16.1Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000004870EUCTR2013-003881-15-SEAnergis SA238
进行中（未招募）
1 期
ong-term follow-up (up to 3 years) to investigate the maintenance of efficacy and safety of AllerT, a drug based on modified peptides of Bet V 1, applied in two different dosages to subjects suffering from birch pollen allergy during the trial AN004Tong-term follow-up of desensitization by Specific ImmunoTherapy (SIT) received during the trial AN004T in subjects allergic to birch pollenMedDRA version: 16.1Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000004870EUCTR2013-003881-15-DKAnergis SA238
进行中（未招募）
不适用
ong-term follow-up (up to 3 years) to investigate the maintenance of efficacy and safety of AllerT, a drug based on modified peptides of Bet V 1, applied in two different dosages to subjects suffering from birch pollen allergy during the trial AN004TEUCTR2013-003881-15-LTAnergis SA238
进行中（未招募）
不适用
ong-term follow-up (up to 3 years) to investigate the maintenance of efficacy and safety of AllerT, a drug based on modified peptides of Bet V 1, applied in two different dosages to subjects suffering from birch pollen allergy during the trial AN004Tong-term follow-up of desensitization by Specific ImmunoTherapy (SIT) received during the trial AN004T in subjects allergic to birch pollenMedDRA version: 16.1Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 100000004870EUCTR2013-003881-15-LVAnergis SA238
已完成
不适用
ong-term follow-up of the multicenter clinical trial using cultivated autologous corneal epithelium (EYE-01M) transplantation for patients with limbal stem-cell deficiencylimbal stem-cell deficiency(LSCD)JPRN-UMIN000039994Japan Tissue Engineering Co., Ltd.10